# reload+after+2024-01-21 21:43:25.436006
address1§400 Fifth Avenue
address2§Suite 210
city§Waltham
state§MA
zip§02451
country§United States
phone§510 745 1700
website§https://www.ardelyx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
fullTimeEmployees§133
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Michael G. Raab', 'age': 58, 'title': 'President, CEO & Director', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 1281500, 'exercisedValue': 0, 'unexercisedValue': 534499}, {'maxAge': 1, 'name': 'Ms. Susan  Rodriguez', 'age': 59, 'title': 'Chief Commercial Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 760772, 'exercisedValue': 0, 'unexercisedValue': 83118}, {'maxAge': 1, 'name': 'Dr. Laura A. Williams M.D., M.P.H.', 'age': 59, 'title': 'Chief Medical Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 873800, 'exercisedValue': 0, 'unexercisedValue': 81840}, {'maxAge': 1, 'name': 'Mr. Justin A. Renz CPA, MBA', 'age': 51, 'title': 'Chief Financial & Operations Officer and Treasurer', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 623700, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Robert  Felsch', 'title': 'Senior VP of Finance & Chief Accounting Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Elizabeth A. Grammer Esq.', 'age': 59, 'title': 'Chief Legal & Administrative Officer and Secretary', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 623700, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Caitlin  Lowie', 'title': 'Vice President of Corporate Communications & Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Charon  Spencer Sr.', 'title': 'Chief Human Resources Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. David P. Rosenbaum', 'age': 62, 'title': 'Chief Development Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 645400, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Robert C. Blanks', 'age': 63, 'title': 'Chief Regulatory Affairs & Quality Assurance Officer', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 590800, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§6
compensationRisk§8
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.928
priceToSalesTrailing12Months§10.649879
currency§USD
dateShortInterest§1702598400
forwardEps§-0.25
pegRatio§-0.68
exchange§NGM
quoteType§EQUITY
shortName§Ardelyx, Inc.
longName§Ardelyx, Inc.
firstTradeDateEpochUtc§1403184600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§419f5034-7b70-3f95-acd4-15f78343e65d
gmtOffSetMilliseconds§-18000000
targetHighPrice§15.0
targetLowPrice§8.0
targetMeanPrice§10.72
targetMedianPrice§10.5
recommendationMean§1.4
recommendationKey§strong_buy
numberOfAnalystOpinions§9
quickRatio§4.786
grossMargins§0.64002997
ebitdaMargins§-0.11833999
trailingPegRatio§None
